O Nível Sérico de Magnésio e o Prognóstico Neurológico Após Acidente Vascular Cerebral Isquêmico Agudo
DOI:
https://doi.org/10.4181/RNC.2012.20.711.5pPalavras-chave:
Níveis Séricos de Magnésio, AVE, Prognóstico NeurológicoResumo
Introdução. O Acidente Vascular Cerebral Isquêmico á a segunda causa mais comum de morte no mundo. Cerca de um terço dos sobreviventes são funcionalmente dependentes em 1 ano. Agentes de proteção cerebral permanecem o principal desafio de pesquisas. Muitos ensaios clínicos tentaram provar a eficácia da administração de magnésio nestes pacientes, mas nenhum investigou a relação entre níveis séricos de magnésio e o prognóstico. Método. Analisamos prospectivamente 83 pacientes através de estudo tipo coorte entre 2009 e 2010 e prognóstico em 30 e 90 dias foi avaliado. Modelo de regressão de Cox e Kaplan Meier foram usados para determinar características subjetivas associadas ao risco de recorrência. Níveis séricos de Magnésio foram dosados diariamente durante a permanência hospitalar. A independência funcional foi definida como níveis nas Escala Prognóstica de Glasgow 4 ou 5 e Escala de Rhankin modificada 0 a 2. Resultados. Magnésio < 1,8 mg/dl foi encontrado em 20 dos 83 pacientes (24%). Não houve efeito de baixos níveis séricos de magnésio nas taxas de independência funcional (28% versus 29%, P=0.84) ou mortalidade (46% versus 45%, P=0.93). Conclusão. Os níveis séricos de Magnésio não foram associados com pior prognóstico em nossa série de pacientes.
Downloads
Métricas
Referências
Murray CJL, Lopez AD. Evidence-Based Health Policy: Lessons from the Global Burden of Disease Study Science 1996;274:740-43.
Shiber JR, Fontane E, Adewale A. Stroke registry: hemorrhagic vs ischemic strokes. Am J Emerg Med 2010; 28:331-3. http://dx.doi.org/10.1016/j.ajem.2008.10.026
Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371(9624):1612-23. http://dx.doi.org/10.1016/S0140-6736(08)60694-7
Lotufo PA, Benseñor IM. Trends of stroke subtypes mortality in Sao Paulo, Brazil (1996–2003). Arq Neuropsiquiatr 2005;63:951-5. http://dx.doi.org/10.1590/S0004-282X2005000600009
Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics – 2010 edition. Oxford: British Heart Foundation, 2010, 156p.
Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001; 19:1612-6. http://dx.doi.org/10.1016/S0140-6736(00)04730-9
Muir KW. Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness. CNS Drugs 2001;15:921-30. http://dx.doi.org/10.2165/00023210-200115120-00002
Lampl Y, Gilad R, Geva D, Eshel Y, Sadeh M. Intravenous administration of magnesium sulfate in acute stroke: a randomised double-blind study. Clin Neuropharmacol 2001;24:11-5. http://dx.doi.org/10.1097/00002826200101000-00003
Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial. Lancet 2004;363:439-45. http://dx.doi.org/10.1016/S0140-6736(04)15490-1
Saver JL, Kidwell C, Eckstein M, Ovbiagele B, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy -- magnesium (FAST-MAG) pilot trial. Stroke 2004; 35:106-8. http://dx.doi.org/10.1161/01.STR.0000124458.98123.52
Toni D, Chamorro A, Kaste M, Keddedy Lees, Wahlgren NG, Hacke W, for the EUSI Executive Committee and the EUSI Writing Committee. Acute Treatment of Ischemic Stroke. Cerebrovasc Dis 2004;17(suppl 2):30-46. http://dx.doi.org/10.1159/000074818
Schellinger PD, Bryan RN, Caplan LR, Detre JA, Edelman RR, Jaigobin C, et al. Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;75(2):177-85. http://dx.doi.org/10.1212/WNL.0b013e3181e7c9dd
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; 2011;42(4):1158-92. http://dx.doi.org/10.1161/STR.0b013e31820a8364
Belfort MA, Moise KJ Jr. Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study. Am J Obstet Gynecol 1992; 167:661-6.
Rasmussen HS, Larsen OG, Meier K, Larsen J. Hemodynamic effects of intravenously administered magnesium on patients with ischemic heart disease. Clin Cardiol 1988;11:824-8. http://dx.doi.org/10.1002/clc.4960111205
Reinhart RA. Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Am Heart J 1991;121:1513-21. http://dx.doi.org/10.1016/0002-8703(91)90160-J
Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985;84:381-91.
Favaron M, Bernardi P. Tissue-specific modulation of the mitochondrial calcium uniporter by magnesium ions. FEBS Lett 1985;183:260-4. http://dx.doi.org/10.1016/0014-5793(85)80789-4
Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intra-arterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85:117-24. http://dx.doi.org/10.3171/jns.1996.85.1.0117
Yang Y, Li Q, Ahmad F, Shuaib A. Survival and histological evaluation of therapeutic window of post- ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000;285:119-22. http://dx.doi.org/10.1016/S0304-3940(00)01048-X
Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-30. http://dx.doi.org/10.1038/jcbfm.1991.170
Wester PO, Asplund K, Eriksson S, Hagg E, Lithner F, Strand T. Infusion of magnesium in patients with acute brain infarction. Acta Neurol Scand 1984;70:143.23.Muir KW, Lees KR. A randomized, double blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995;26:183-8. http://dx.doi.org/10.1161/01.STR.26.7.1183
Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998; 29:918-23. http://dx.doi.org/10.1161/01.STR.29.5.918
Lampl Y, Gilad R, Geva D, Eshel Y, Sadeh M. Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. Clin Neuropharmacol 2001;24:11-15. http://dx.doi.org/10.1097/00002826200101000-00003
Van Sweiten JC, Koudstaal PJ, Visser MC, Shouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicaps in stroke patients. Stroke 1988;19(5):604-7. http://dx.doi.org/10.1161/01.STR.19.5.604
Chi OZ, Pollak P, Weiss HR. Effects of magnesium sulfate and nimodipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. Arch Int Pharmacodyn Ther 1990;304:196-205.
Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A. Mg+2–Ca+2 interactions in contractility of vascular smooth muscle: Mg+2 versus organic calcium channel blockers on myogenic tone and against inducedresponsiveness of blood vessels. Can J Physiol Pharmacol 1987;65:129-45. http://dx.doi.org/10.1139/y87120
Davis J, Watkins JC. Effect of magnesium ions on the responses of spinal neurons to excitatory amino acids and acetylcholine. Brain Res 1977;130:364-8. http://dx.doi.org/10.1016/0006-8993(77)90284-0
Mori H, Masaki H, Yamakura T, Mishina M. Identification by mutagenesis of a Mg (2+)-block site of the NMDA receptor channel. Nature 1992;358:673-5. http://dx.doi.org/10.1038/358673a0
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2012-09-30